These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cefepime pharmacokinetics in critically ill children and young adults undergoing continuous kidney replacement therapy. Pavia K; Hambrick HR; Paice K; Tang P; Punt N; Kaplan J; Goldstein SL; Vinks AA; Mizuno T; Tang Girdwood S J Antimicrob Chemother; 2023 Sep; 78(9):2140-2147. PubMed ID: 37466170 [TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Peng Y; Cheng Z; Xie F Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753 [TBL] [Abstract][Full Text] [Related]
8. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. Broeker A; Wicha SG; Dorn C; Kratzer A; Schleibinger M; Kees F; Heininger A; Kees MG; Häberle H Crit Care; 2018 Dec; 22(1):341. PubMed ID: 30558639 [TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy. He S; Cheng Z; Xie F Drug Des Devel Ther; 2022; 16():13-22. PubMed ID: 35023902 [TBL] [Abstract][Full Text] [Related]
10. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309 [TBL] [Abstract][Full Text] [Related]
11. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study. Chaijamorn W; Charoensareerat T; Srisawat N; Pattharachayakul S; Boonpeng A J Intensive Care; 2018; 6():61. PubMed ID: 30221005 [TBL] [Abstract][Full Text] [Related]
12. Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy. Wang C; Chen J; Yang B; Li S; Zhang Y; Chen L; Wang T; Dong Y Pharmacotherapy; 2023 Mar; 43(3):180-188. PubMed ID: 36714991 [TBL] [Abstract][Full Text] [Related]
13. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations. Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811 [TBL] [Abstract][Full Text] [Related]
14. Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy. Kalaria S; Williford S; Guo D; Shu Y; Medlin C; Li M; Yeung SYA; Ali F; Jean W; Gopalakrishnan M; Heavner M Pharmacotherapy; 2021 Feb; 41(2):205-211. PubMed ID: 33438291 [TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study. Novy E; Abdul-Aziz MH; Cheng V; Burrows F; Buscher H; Corley A; Diehl A; Gilder E; Levkovich BJ; McGuinness S; Ordonez J; Parke R; Parker S; Pellegrino V; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA Antimicrob Agents Chemother; 2024 Jan; 68(1):e0120123. PubMed ID: 38063399 [TBL] [Abstract][Full Text] [Related]
16. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy. Thy M; Urien S; Foissac F; Bouazza N; Gana I; Bille E; Béranger A; Toubiana J; Berthaud R; Lesage F; Renolleau S; Tréluyer JM; Benaboud S; Oualha M Antimicrob Agents Chemother; 2022 Dec; 66(12):e0113522. PubMed ID: 36342152 [TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing. Al-Shaer MH; Neely MN; Liu J; Cherabuddi K; Venugopalan V; Rhodes NJ; Klinker K; Scheetz MH; Peloquin CA Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601155 [TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy. Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189 [TBL] [Abstract][Full Text] [Related]
19. Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing. Gatti M; Giannella M; Raschi E; Viale P; De Ponti F J Antimicrob Chemother; 2021 Jan; 76(1):199-205. PubMed ID: 33057628 [TBL] [Abstract][Full Text] [Related]
20. Association between continuous renal replacement therapy and 28-day mortality of critically ill patients with COVID-19 receiving mechanical ventilation. Xu X; Liu K; Cheng P; Huang Y; Huang C; Wu W; Xing C; Mao H; Liu Y Clin Nephrol; 2021 Oct; 96(4):207-215. PubMed ID: 34236306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]